MX2015005875A - Polipeptidos derivados de tgfbeta y sus usos. - Google Patents
Polipeptidos derivados de tgfbeta y sus usos.Info
- Publication number
- MX2015005875A MX2015005875A MX2015005875A MX2015005875A MX2015005875A MX 2015005875 A MX2015005875 A MX 2015005875A MX 2015005875 A MX2015005875 A MX 2015005875A MX 2015005875 A MX2015005875 A MX 2015005875A MX 2015005875 A MX2015005875 A MX 2015005875A
- Authority
- MX
- Mexico
- Prior art keywords
- tgfã
- diseases
- alk5
- interact
- ability
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con las ramas de la Biotecnología y particularmente con polipéptidos mutados de la molécula TGFß cuya secuencia primaria tiene una alta homología con la secuencia del TGFß humano; estas muteínas pierden la capacidad de interacción con ALK5 pero conservan la interacción con el resto de los receptores que forman parte del complejo receptor (TßRII y TßRIII); tienen la propiedad de antagonizar la señalización del todas las variantes naturales de los ligandos TGFß, dependiente del reclutamiento de ALK5 en el complejo receptor y tienen un efecto inmunomodulador; la presente invención se relaciona con composiciones farmacéuticas que comprenden como principio activo los polipéptidos o proteínas de fusión divulgados y con el uso terapéutico de los polipéptidos, proteínas de fusión y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como el cáncer, enfermedades que cursan con fibrosis y en enfermedades infecciosas crónicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120158A CU24181B1 (es) | 2012-11-09 | 2012-11-09 | POLIPÉPTIDOS DERIVADOS DEL TGFß |
| PCT/CU2013/000007 WO2014071894A1 (es) | 2012-11-09 | 2013-10-30 | POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005875A true MX2015005875A (es) | 2015-09-10 |
| MX366060B MX366060B (es) | 2019-06-26 |
Family
ID=49765213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005875A MX366060B (es) | 2012-11-09 | 2013-10-30 | Polipéptidos derivados de tgfbeta y sus usos. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9701730B2 (es) |
| EP (1) | EP2918284B1 (es) |
| JP (2) | JP6298823B2 (es) |
| KR (1) | KR102093494B1 (es) |
| CN (1) | CN104902916B (es) |
| AR (1) | AR093391A1 (es) |
| AU (1) | AU2013344022B2 (es) |
| BR (1) | BR112015010145B1 (es) |
| CA (1) | CA2887455C (es) |
| CL (1) | CL2015001252A1 (es) |
| CO (1) | CO7400865A2 (es) |
| CU (1) | CU24181B1 (es) |
| EA (1) | EA031990B1 (es) |
| ES (1) | ES2857176T3 (es) |
| IL (1) | IL238621B (es) |
| JO (1) | JO3502B1 (es) |
| MX (1) | MX366060B (es) |
| MY (1) | MY173078A (es) |
| NZ (1) | NZ707850A (es) |
| PE (1) | PE20150890A1 (es) |
| PH (1) | PH12015500807A1 (es) |
| SG (1) | SG11201502980VA (es) |
| TN (1) | TN2015000129A1 (es) |
| TW (1) | TWI615404B (es) |
| UA (1) | UA115678C2 (es) |
| WO (1) | WO2014071894A1 (es) |
| ZA (1) | ZA201504462B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3541409B1 (en) * | 2016-11-18 | 2025-01-22 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling |
| PL238850B1 (pl) * | 2017-10-19 | 2021-10-11 | Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia | Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna |
| CN119285746B (zh) * | 2024-10-24 | 2026-01-30 | 湖南中晟全肽生物科技股份有限公司 | 作为TGF-β受体激动剂肽的化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999065948A1 (en) * | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| AU778998B2 (en) | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
| US6677432B1 (en) * | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US7470769B2 (en) * | 2004-06-30 | 2008-12-30 | Molecular Logix, Inc. | Epidermal growth factor receptor antagonists and methods of use |
| US7795389B2 (en) * | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| WO2006076041A2 (en) * | 2005-01-11 | 2006-07-20 | Molecular Logix, Inc. | Pan-her antagonists and methods of use |
| GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| CN102958531A (zh) * | 2010-04-22 | 2013-03-06 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 高亲和力瘦蛋白和瘦蛋白拮抗剂 |
-
2012
- 2012-11-09 CU CU20120158A patent/CU24181B1/es active IP Right Grant
-
2013
- 2013-10-30 SG SG11201502980VA patent/SG11201502980VA/en unknown
- 2013-10-30 PE PE2015000549A patent/PE20150890A1/es not_active Application Discontinuation
- 2013-10-30 MY MYPI2015701369A patent/MY173078A/en unknown
- 2013-10-30 WO PCT/CU2013/000007 patent/WO2014071894A1/es not_active Ceased
- 2013-10-30 BR BR112015010145-3A patent/BR112015010145B1/pt not_active IP Right Cessation
- 2013-10-30 KR KR1020157011131A patent/KR102093494B1/ko not_active Expired - Fee Related
- 2013-10-30 MX MX2015005875A patent/MX366060B/es active IP Right Grant
- 2013-10-30 EP EP13805228.7A patent/EP2918284B1/en not_active Not-in-force
- 2013-10-30 NZ NZ707850A patent/NZ707850A/en not_active IP Right Cessation
- 2013-10-30 UA UAA201505566A patent/UA115678C2/uk unknown
- 2013-10-30 JP JP2015540045A patent/JP6298823B2/ja not_active Expired - Fee Related
- 2013-10-30 ES ES13805228T patent/ES2857176T3/es active Active
- 2013-10-30 AU AU2013344022A patent/AU2013344022B2/en not_active Ceased
- 2013-10-30 EA EA201590914A patent/EA031990B1/ru not_active IP Right Cessation
- 2013-10-30 CA CA2887455A patent/CA2887455C/en active Active
- 2013-10-30 CN CN201380058181.7A patent/CN104902916B/zh not_active Expired - Fee Related
- 2013-10-30 US US14/440,627 patent/US9701730B2/en not_active Expired - Fee Related
- 2013-11-03 JO JOP/2013/0317A patent/JO3502B1/ar active
- 2013-11-07 TW TW102140494A patent/TWI615404B/zh not_active IP Right Cessation
- 2013-11-07 AR ARP130104078A patent/AR093391A1/es active IP Right Grant
-
2015
- 2015-04-03 TN TNP2015000129A patent/TN2015000129A1/fr unknown
- 2015-04-13 PH PH12015500807A patent/PH12015500807A1/en unknown
- 2015-04-28 CO CO15095702A patent/CO7400865A2/es unknown
- 2015-05-04 IL IL238621A patent/IL238621B/en not_active IP Right Cessation
- 2015-05-08 CL CL2015001252A patent/CL2015001252A1/es unknown
- 2015-06-08 ZA ZA2015/04462A patent/ZA201504462B/en unknown
-
2018
- 2018-02-26 JP JP2018031896A patent/JP6608473B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| MY162324A (en) | Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| IN2014KN03063A (es) | ||
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| MX2016010951A (es) | Proteinas de fc multimericas. | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| MY166157A (en) | Antibodies to bradykinin b1 receptor ligands | |
| IN2014DN06920A (es) | ||
| MX378431B (es) | Uso terapèutico de proteìnas morfogenèticas òseas. | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| GB201118201D0 (en) | Novel peptides | |
| EA201300592A1 (ru) | Ингибиторы апоптоза и их применение | |
| UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
| TN2015000129A1 (en) | POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| IT201700009222A1 (it) | Composizione per la preparazione del paziente per la colonscopia virtuale | |
| MX352456B (es) | Lotes de adenovirus recombinantes con extremos alterados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |